Neumora Therapeutics, Inc. (NMRA) Dividend History

Company News

• Kuehn Law Encourages Investors of Grocery Outlet Holding Corp. to Contact Law Firm

  Kuehn Law, a shareholder litigation law firm, is investigating whether certain officers and directors of Grocery Outlet Holding Corp. (GO) breached their fiduciary duties to shareholders. The firm is also investigating Neumora Therapeutics, Inc. (NMRA) and Solaris Energy Infrastructure, Inc. (SLRS).

  GlobeNewswire Inc.

  Featured Companies: GO SEI
• Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

  Kuehn Law is investigating whether officers and directors of Neumora Therapeutics, Inc. (NMRA) breached their fiduciary duties to shareholders by allegedly misrepresenting or failing to disclose information related to the company's Phase Two and Three trials for its drug Navacaprant.

  GlobeNewswire Inc.
• Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA

  Faruqi & Faruqi, LLP is investigating potential claims against Neumora Therapeutics, Inc. (NMRA) for making false and/or misleading statements regarding its experimental depression treatment, which failed in a Phase III trial.

  GlobeNewswire Inc.
• NMRA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit

  A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (NMRA) on behalf of investors who purchased or acquired Neumora common stock in connection with the company's initial public offering. The lawsuit alleges that Neumora made materially false and/or misleading statements in its offering documents.

  GlobeNewswire Inc.
• NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

  A class action lawsuit has been filed against Neumora Therapeutics, Inc. (NMRA) alleging that the company's IPO documents failed to disclose significant risks and uncertainties regarding its Phase Three Program, including the KOASTAL-1 study.

  GlobeNewswire Inc.